Skip to main content
. Author manuscript; available in PMC: 2009 Apr 30.
Published in final edited form as: J Neuroimmune Pharmacol. 2008 Jul 25;3(4):257–264. doi: 10.1007/s11481-008-9117-3

Fig. 4.

Fig. 4

Aprepitant in dose-dependent fashion inhibits HIV-1 (Bal) infection of macrophages. Seven-day-cultured macrophages were treated with aprepitant at indicated concentrations (10-9 M to 5×10-5 M) for 2 h and then infected with HIV-1 Bal strain. Cell viability was detected with MTS assay on day 12 post-infection. HIV-1 RT activity was determined at day 12 post-infection. The data shown are presented as the mean ± SD of triplicate cultures, representative of three experiments using macrophage from three donors (aprepitant vs. control: *p<0.05)